Get the Stockscreener App
10.25
0.58%
-0.06
After Hours:
10.33
0.08
+0.78%
Adma Biologics Inc stock is traded at $10.25, with a volume of 6.49M.
It is down -0.58% in the last 24 hours and up +11.53% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$10.31
Open:
$10.43
24h Volume:
6.49M
Relative Volume:
1.10
Market Cap:
$2.38B
Revenue:
$510.17M
Net Income/Loss:
$146.93M
P/E Ratio:
17.11
EPS:
0.599
Net Cash Flow:
$27.51M
1W Performance:
-5.96%
1M Performance:
+11.53%
6M Performance:
-33.31%
1Y Performance:
-56.77%
1-Day Range:
$10.05
$10.56
1-Week Range:
$10.05
$10.88
52-Week Range:
$7.2101
$23.98
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
10.25 | 2.40B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth? - Yahoo Finance
CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weighing ADMA Biologics (ADMA) After A 56% One-Year Share Price Decline - Yahoo Finance
Assessing ADMA Biologics (ADMA) Valuation As Securities Investigations Follow Channel Stuffing Allegations - Yahoo Finance
ADMA Secures FDA Approval for Asceniv Expansion - GuruFocus
ADMA Biologics’ ASCENIV Receives FDA Approval to Treat Pediatric Immunodeficiency Patients Aged 2 and Older - Minichart
ADMA Biologics Receives FDA Approval to Expand Asceniv Label for Pediatric Patients - Moomoo
ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label - TipRanks
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older - The Manila Times
Children as young as 2 gain access to ADMA's ASCENIV after FDA approval - Stock Titan
[8-K] ADMA BIOLOGICS, INC. Reports Material Event - Stock Titan
ADMA Biologics Announces FDA Approval to Expand the Label - GlobeNewswire
$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% - GlobeNewswire
BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - GlobeNewswire Inc.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ... - Caledonian Record
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Report And Legal Investigation - Sahm
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - PR Newswire
MSN Money - MSN
Earnings Preview: ADMA to Report Financial Results Post-market on May 06 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ... - Caledonian Record
ADMA stock downgraded by Cantor as ‘channel stuffing’ claims shake investor confidence - MSN
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vanguard (NASDAQ: ADMA) reports 12.11M shares, 5.08% stake - Stock Titan
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Immunoglobulin Market Leading Players AnalysisADMA - openPR.com
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
Investigation into ADMA Biologics for Potential Securities Fraud - Intellectia AI
ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Research - MarketBeat
ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday - MarketBeat
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA ... - Caledonian Record
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Yahoo Finance
ADMA Biologics Investor News: If You Have Suffered Losses - GlobeNewswire
ADMA Biologics rejects claims made in short-seller report - MSN
ADMA Biologics drops amid short report from Culper Research - MSN
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
Q2 2025 ADMA Biologics Inc Earnings Call Transcript - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: Could an 83% Potential Upside Be Within Reach? - DirectorsTalk Interviews
Calamos Advisors LLC Increases Stock Position in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics gains after refuting short seller claims - MSN
Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA) - Yahoo Finance
Does ADMA Biologics' growth story outweigh short-seller concerns? - MSN
ADMA stock drops 6% after Culper Research alleges channel stuffing - MSN
Down 27% in 4 weeks, here's why Adma Biologics (ADMA) looks ripe for a turnaround - MSN
Wall Street Zen Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy - MarketBeat
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):